Latest news with #OrganonCo
Yahoo
21-07-2025
- Business
- Yahoo
Organon & Co. (OGN) Restructures, Expands in Women's Health and Biosimilars
We recently published Organon & Co stands tenth on our list and has expanded in women's health and biosimilars. Organon & Co. (NYSE:OGN), a global healthcare company specializing in women's health, biosimilars, and established brands, underwent major changes in 2025. On May 1, the company slashed its quarterly dividend from $0.28 to $0.02 per share (annualized from $1.12 to $0.08) to prioritize debt reduction following its $1.2 billion acquisition of Dermavant in late 2024. This shift led to a 27% drop in stock price and a shareholder lawsuit alleging securities fraud due to prior reassurances about maintaining the dividend. In April, Organon & Co. (NYSE:OGN) laid off 93 employees at its Jersey City headquarters, part of an ongoing global restructuring that began in 2023 and impacted around 5% of the workforce in early 2025. The restructuring responds partly to the loss of exclusivity for Atozet, the company's second-largest product, which saw sales drop 9% in 2024, with continued decline expected. A robotic arm picking up a product assembly line, displaying the company's consumer healthcare and wellness offerings. That same month, the corporation acquired U.S. commercial rights to TOFIDENCE, a biosimilar to ACTEMRA (tocilizumab), from Biogen, expanding its immunology biosimilars portfolio. Organon & Co. (NYSE:OGN) will pay upfront fees, royalties, and milestone payments, while Bio-Thera Solutions retains U.S. manufacturing rights. TOFIDENCE enters a competitive space alongside Celltrion's Avtozma and Fresenius Kabi's Tyenne. On June 12, the business partnered with Evvy to increase access to XACIATO (clindamycin phosphate) vaginal gel 2%, reaffirming its women's health focus. Its flagship product, Nexplanon, posted 14% growth last quarter. In leadership news, Ramona A. Sequeira, President at Takeda, will join the company's Board on July 1, serving on the Talent Committee, as the company continues its strategic transformation. While we acknowledge the potential of OGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
21-07-2025
- Business
- Globe and Mail
Organon & Co. (OGN) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before July 22, 2025
New York, New York--(Newsfile Corp. - July 21, 2025) - If you suffered a loss on your Organon & Co. (NYSE: OGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: or contact Joseph E. Levi, Esq. via email at jlevi@ or call (212) 363-7500 to speak to our team of experienced shareholder advocates. Cannot view this video? Visit: THE LAWSUIT: A class action securities lawsuit was filed against Organon & Co. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between October 31, 2024 and April 30, 2025. CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Organon's priorities, particularly, related to capital allocation through quarterly dividends. Notably, defendants concealed the high priority of Organon's debt reduction strategy following the Company's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend. Following this news, the price of Organon's common stock declined dramatically. From a closing market price of $12.93 per share on April 30, 2025, Organon's stock price fell to $9.45 per share on May 1, 2025, a decline of more than 27% in the span of just a single day. WHAT'S NEXT? If you suffered a loss in Organon stock during the relevant time frame - even if you still hold your shares - go to to learn about your rights to seek a recovery. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
Globe and Mail
18-07-2025
- Business
- Globe and Mail
Securities Lawsuit Alert: Organon & Co. (OGN) - Contact Levi & Korsinsky Before July 22, 2025
New York, New York--(Newsfile Corp. - July 18, 2025) - If you suffered a loss on your Organon & Co. (NYSE: OGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: or contact Joseph E. Levi, Esq. via email at jlevi@ or call (212) 363-7500 to speak to our team of experienced shareholder advocates. Cannot view this video? Visit: THE LAWSUIT: A class action securities lawsuit was filed against Organon & Co. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between October 31, 2024 and April 30, 2025. CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Organon's priorities, particularly, related to capital allocation through quarterly dividends. Notably, defendants concealed the high priority of Organon's debt reduction strategy following the Company's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend. Following this news, the price of Organon's common stock declined dramatically. From a closing market price of $12.93 per share on April 30, 2025, Organon's stock price fell to $9.45 per share on May 1, 2025, a decline of more than 27% in the span of just a single day. WHAT'S NEXT? If you suffered a loss in Organon stock during the relevant time frame - even if you still hold your shares - go to to learn about your rights to seek a recovery. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
